| Literature DB >> 31382015 |
Christoph Kraus1, Daniel Wasserman1, Ioline D Henter1, Elia Acevedo-Diaz1, Bashkim Kadriu2, Carlos A Zarate1.
Abstract
Recent research demonstrating that the glutamatergic modulator ketamine has rapid, robust, and sustained antidepressant effects has been a turning point in drug discovery for depression. The recent FDA approval of esketamine for adults with treatment-resistant major depressive disorder (MDD) has further underscored the relevance of this agent in spurring investigation into novel and mechanistically distinct agents for use in depression. Over the past two decades, ketamine research has ushered in a new wave of studies seeking to not only identify its mechanism of action but also to examine the antidepressant potential of novel or repurposed agents. This article reviews the approaches that have proven particularly fruitful for the field of neuropsychiatry. Published by Elsevier Ltd.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31382015 PMCID： PMC6842425 DOI： 10.1016/j.drudis.2019.07.007
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851